- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: May 2019
- Public Summary Document (PSD) May 2019 PBAC Meeting - PDF
- Public Summary Document (PSD) May 2019 PBAC Meeting - Word
Inotuzumab ozogamicin – May 2019
Inotuzumab ozogamicin: Powder for I.V. infusion, 1 mg; Besponsa®
Last updated
1 November 2019